

NORTHEAST LOUISIANA SICKLE CELL ANEMIA FOUNDATION, INC.

MONROE, LOUISIANA

FINANCIAL STATEMENTS

FOR THE YEAR ENDED

JUNE 30, 2020

NORTHEAST LOUISIANA SICKLE CELL ANEMIA FOUNDATION, INC.
JUNE 30, 2020

CONTENTS

	<u>PAGE</u>
Independent Auditors' Report.....	1-3
Statement of Financial Position.....	4
Statement of Activities.....	5
Statement of Functional Expenses.....	6
Statement of Cash Flows.....	7
Notes to Financial Statements.....	8-18
SUPPLEMENTAL INFORMATION	
Schedule I - Schedule of Financial Position.....	19-20
Schedule II - Schedule of Activities.....	21-22
Schedule III - Schedule of Cash Flows.....	23-24
Schedule IV - Schedule of Functional Expenses.....	25-27
Schedule V - Schedule of Compensation, Benefits, and Other Payments to Agency Head or Chief Executive Officer.....	28
COMPLIANCE REPORTS	
Independent Auditors' Report on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance with <i>Government Auditing Standards</i>	29-30
SCHEDULE OF FINDINGS AND QUESTIONED COSTS.....	31
SCHEDULE OF PRIOR YEAR FINDINGS.....	32

JOHNSON, PERRY, ROUSSEL & CUTHBERT, L.L.P.

ROWLAND H. PERRY, CPA, APC
CHARLES L. JOHNSON, JR., CPA
VIOLET M. ROUSSEL, CPA, APC
JAY CUTHBERT, CPA, APAC

PAM BATTAGLIA, CPA
DAWN WHITSTINE, CPA
JOHN R. FORSELL, IV, CPA



America Counts on CPAs®

Certified Public Accountants

3007 Armand Street

Monroe, Louisiana 71201

Telephone (318) 322-5156 or (318) 323-1411

Facsimile (318) 323-6331

- Accounting & Auditing
 - HUD Audits
 - Non-Profit Organizations
 - Governmental Organizations
- Business & Financial Planning
- Tax Preparation & Planning
 - Individual & Partnership
 - Corporate & Fiduciary
- Bookkeeping & Payroll Services

INDEPENDENT AUDITORS' REPORT

Board of Directors
Northeast Louisiana Sickle Cell Anemia Foundation, Inc.
Monroe, Louisiana

Report on the Financial Statements

We have audited the accompanying financial statements of the Northeast Louisiana Sickle Cell Anemia Foundation, Inc. (a nonprofit organization), which comprise the statement of financial position as of June 30, 2020, and the related statements of activities, functional expenses, and cash flows for the year ended, and the related notes to the financial statements.

Management's Responsibility for the Financial Statements

Management is responsible for the preparation and fair presentation of these financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

Auditors' Responsibility

Our responsibility is to express an opinion on these financial statements based on conducting the audit in accordance with auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatements.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditors' judgment, including the

assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion on the Statement of Financial Position

In our opinion, the statement of financial position referred to in the first paragraph presents fairly, in all material respects, the financial position of the Northeast Louisiana Sickle Cell Anemia Foundation, Inc. as of June 30, 2020, and the changes in its net assets and its cash flows for the year then ended in accordance with accounting principles generally accepted in the United States of America.

Other Information

Our audit was conducted for the purpose of forming an opinion on the financial statements as a whole. The schedules I, II, III, IV and V on pages 19 through 28 are presented for purposes of additional analysis and are not a required part of the financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the financial statements. The information has been subjected to the auditing procedures applied in the audit of the financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the financial statements or to the financial statements themselves, and other additional procedures in accordance with auditing standards generally accepted in the United States of America. In our opinion, the information is fairly stated in all material respects in relation to the financial statements as a whole.

Other Reporting Required by Government Auditing Standards

In accordance with *Government Auditing Standards*, we have also issued our report dated October 26, 2020 on our consideration of the Northeast Louisiana Sickle Cell Anemia Foundation, Inc.'s internal

control over financial reporting and on our tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements and other matters. The purpose of that report is to describe the scope of our testing of internal control over financial reporting and compliance and the results of that testing, and not to provide an opinion on the internal control over financial reporting or on compliance. That report is an integral part of an audit performed in accordance with Government Auditing Standards in considering the Northeast Louisiana Sickle Cell Anemia Foundation, Inc.'s internal control over financial reporting and compliance.

Johnson Perry Roussel & Cuthbert, LLP

JOHNSON, PERRY, ROUSSEL & CUTHBERT, L.L.P.
CERTIFIED PUBLIC ACCOUNTANTS
October 26, 2020

NORTHEAST LOUISIANA SICKLE CELL ANEMIA FOUNDATION, INC.
STATEMENT OF FINANCIAL POSITION
AS OF JUNE 30, 2020

ASSETS

CURRENT ASSETS

Cash and Cash Equivalents \$ 56,015

TOTAL CURRENT ASSETS 56,015

FIXED ASSETS

Land, Buildings, and Equipment, Net 137,645

NET FIXED ASSETS 137,645

TOTAL ASSETS 193,660

LIABILITIES & NET ASSETS

CURRENT LIABILITIES

Deferred Revenue 149,441

Line of Credit 4,118

TOTAL CURRENT LIABILITIES 153,559

TOTAL LIABILITIES 153,559

NET ASSETS

Without Donor Restrictions 34,895

With Donor Restrictions 5,206

TOTAL NET ASSETS 40,101

TOTAL LIABILITIES AND
NET ASSETS \$ 193,660

See Independent Auditors' Report and Accompanying Notes.

- 4 -

JOHNSON, PERRY, ROUSSEL & CUTHBERT, L.L.P.
CERTIFIED PUBLIC ACCOUNTANTS

NORTHEAST LOUISIANA SICKLE CELL ANEMIA FOUNDATION, INC.
STATEMENT OF ACTIVITIES
FOR THE YEAR ENDED JUNE 30, 2020

<u>SUPPORT AND REVENUE</u>	<u>Without Donor Restrictions</u>	<u>With Donor Restrictions</u>	<u>Total</u>
<u>SUPPORT</u>			
Contributions	\$ 26,629	\$ -	\$ 26,629
Grants	-	66,920	66,920
Other Income	10,337	-	10,337
Net Assets Released from Restrictions	66,920	(66,920)	-
<u>TOTAL SUPPORT</u>	<u>103,886</u>	<u>-</u>	<u>103,886</u>
<u>REVENUE</u>			
Special Events	(4,007)	-	(4,007)
Interest Revenue	517	-	517
<u>TOTAL REVENUE</u>	<u>(3,490)</u>	<u>-</u>	<u>(3,490)</u>
<u>TOTAL SUPPORT AND REVENUE</u>	<u>100,396</u>	<u>-</u>	<u>100,396</u>
<u>EXPENSES</u>			
<u>PROGRAM SERVICES</u>	<u>58,790</u>	<u>-</u>	<u>58,790</u>
<u>SUPPORTING SERVICES</u>			
Management & General	56,550	-	56,550
<u>TOTAL SUPPORTING SERVICES</u>	<u>56,550</u>	<u>-</u>	<u>56,550</u>
<u>TOTAL FUNCTIONAL EXPENSES</u>	<u>115,340</u>	<u>-</u>	<u>115,340</u>
Change in Net Assets	(14,944)	-	(14,944)
<u>NET ASSETS AT BEGINNING OF YEAR</u>	<u>49,839</u>	<u>5,206</u>	<u>55,045</u>
<u>NET ASSETS AT END OF YEAR</u>	<u>\$ 34,895</u>	<u>\$ 5,206</u>	<u>\$ 40,101</u>

See Independent Auditors' Report and Accompanying Notes.

NORTHEAST LOUISIANA SICKLE CELL ANEMIA FOUNDATION, INC.
STATEMENT OF FUNCTIONAL EXPENSES
FOR THE YEAR ENDED JUNE 30, 2020

	General and Administrative	Program	Total
Personnel Costs			
Salaries and Wages	\$ 25,826	\$ 27,627	\$ 53,453
Payroll Taxes and Other Fringe Benefits	2,255	2,413	4,668
Total Personnel Costs	<u>28,081</u>	<u>30,040</u>	<u>58,121</u>
Other Expenses			
Advertising	56	65	121
Automobile Expense	115	135	250
Bank Service Charges	238	279	517
Depreciation Expense	4,798	5,633	10,431
Insurance	1,750	2,055	3,805
Interest	213	249	462
Maintenance	571	671	1,242
Office Expense	3,586	4,203	7,789
Other Program Expense	32	38	70
Postage and Delivery	62	72	134
Printing and Publication	500	588	1,088
Professional Fees	9,838	-	9,838
Repairs and Maintenance	373	438	811
Specific Assistance to Individuals	-	6,884	6,884
Storage	247	291	538
Telephone	790	927	1,717
Travel	-	-	0
Utilities	5,300	6,222	11,522
<u>TOTAL EXPENSES</u>	<u>\$ 56,550</u>	<u>\$ 58,790</u>	<u>\$ 115,340</u>

See Independent Auditors' Report and Accompanying Notes.

- 6 -

JOHNSON, PERRY, ROUSSEL & CUTHBERT, L.L.P.
CERTIFIED PUBLIC ACCOUNTANTS

NORTHEAST LOUISIANA SICKLE CELL ANEMIA FOUNDATION, INC.
STATEMENT OF CASH FLOWS
FOR THE YEAR ENDED JUNE 30, 2020

CASH FLOWS FROM OPERATING ACTIVITIES:

Change in Net Assets	\$ (14,944)
Adjustments to Reconcile Change in Unrestricted Net Assets to Net Cash Provided by Operating Activities	
Depreciation and Amortization	10,431
(Increase) Decrease in:	
Receivables	4,900
Increase (Decrease) in:	
Deferred Revenue	17,034
Accrued Liabilities	0

<u>NET CASH PROVIDED (USED) BY OPERATING ACTIVITIES</u>	17,421
---	--------

CASH FLOWS FROM INVESTING ACTIVITIES:

Purchase of Fixed Assets	(20,907)
Proceeds from Certificate of Deposits	21,986

<u>NET CASH PROVIDED (USED) BY INVESTING ACTIVITIES</u>	1,079
---	-------

CASH FLOWS FROM FINANCING ACTIVITIES:

Proceeds from Line of Credit	239
------------------------------	-----

<u>NET CASH PROVIDED (USED) BY FINANCING ACTIVITIES</u>	239
---	-----

<u>NET INCREASE (DECREASE) IN CASH</u>	18,739
--	--------

<u>CASH AT BEGINNING OF PERIOD</u>	37,276
------------------------------------	--------

<u>CASH AT END OF PERIOD</u>	\$ 56,015
------------------------------	-----------

Interest Paid	462
Income Taxes Paid	0

See Independent Auditors' Report and Accompanying Notes.

NORTHEAST LOUISIANA SICKLE CELL ANEMIA FOUNDATION, INC.
NOTES TO FINANCIAL STATEMENTS
JUNE 30, 2020

NOTE 1 - NATURE OF ACTIVITIES AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES:

Nature of Activities

The Northeast Louisiana Sickle Cell Anemia Foundation, Inc. (the Foundation) is a private nonprofit organization domiciled in the State of Louisiana at Monroe, Louisiana. The Foundation is recognized as a tax-exempt (non-profit) organization under section 501(c)(3) of the Internal Revenue Service Code. The Foundation is supported primarily through state and private grants, contributions and donations from members, and fundraisers. The objective of the Foundation is primarily to provide services to persons born with sickle cell anemia, a hereditary disorder. Such services include educational programs, patient assistance programs, genetic counseling, research, and social services. A Board of Directors consisting of fifteen (15) members governs the Foundation. The Board Members receive no compensation.

Method of Accounting

The financial statements have been prepared on the accrual method of accounting and in conformity with the standards promulgated by the American Institute of Certified Public Accountants in its *Audit and Accounting Guide for Not-for-Profit Organizations*.

Basis of Presentation

The financial statements have been prepared in accordance with U.S generally accepted accounting principles ("US GAAP"), which require the Foundation to report information regarding its financial position and activities according to the following net asset classifications:

Net Assets without donor restrictions: Net assets that are not subject to donor-imposed restrictions and may be expended for any purpose in performing the primary objectives of the Foundation. These net assets may be used at the discretion of the Foundation and the board of directors.

NORTHEAST LOUISIANA SICKLE CELL ANEMIA FOUNDATION, INC.
NOTES TO FINANCIAL STATEMENTS (CONTINUED)
JUNE 30, 2020

NOTE 1 - NATURE OF ACTIVITIES AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: (Continued)

Basis of Presentation (Continued)

Net Assets with donor restrictions: Net assets subject to stipulations imposed by donors, and grantors. Some donor restrictions are temporary in nature; those restrictions will be met by actions of the Foundation or by the passage of time. Other donor restrictions are perpetual in nature, whereby the donor has stipulated the funds be maintained in perpetuity. Donor restricted contributions are reported as increases in net assets with donor restrictions. When a restriction expires, net assets are reclassified from net assets with donor restrictions to net assets without donor restrictions in the statement of activities.

Promises to Give and Contributions

Contributions are recognized when the donor makes a promise to give to the Foundation that is, in substance, unconditional. Contributions that are restricted by the donor are reported as increases in net assets without donor restrictions if the restrictions expire in the fiscal year in which the contributions are recognized. All other donor-restricted contributions are reported as increases in net assets with donor restrictions depending on the nature of the restrictions. When a restriction expires, net assets with donor restrictions are reclassified to net assets without donor restrictions.

Revenue Recognition

Revenue from Exchange Transactions: The Foundation recognizes revenue in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Update (ASU) 2014-09, *Revenue from Contracts with Customers*, as amended. ASU 2014-09 applies to exchange transactions with customers that are bound by contracts or similar arrangements and establishes a performance obligation approach to revenue recognition. The Foundation records the following exchange transaction revenue in its statements of activities and changes in net assets for the year ending June 30, 2020:

NORTHEAST LOUISIANA SICKLE CELL ANEMIA FOUNDATION, INC.
NOTES TO FINANCIAL STATEMENTS (CONTINUED)
JUNE 30, 2020

NOTE 1 - NATURE OF ACTIVITIES AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: (Continued)

Revenue Recognition (Continued)

Special Fundraising Event Revenue

The Foundation conducts special events in which a portion of the gross proceeds paid by the participant represents payment for the direct cost of the benefits received by the participant at the event—the exchange component, and a portion represents a contribution to the Foundation. Unless a verifiable objective means exists to demonstrate otherwise, the fair value of meals and entertainment provided at special events is measured at the actual cost to the Foundation. The contribution component is the excess of the gross proceeds over the fair value of the direct donor benefit. The direct costs of the special events, which ultimately benefit the donor rather than the Foundation, are recorded as costs of direct donor benefits in the (consolidated) statement of activities and changes in net assets. The performance obligation is delivery of the event, which is usually accompanied by a presentation. The event fee is set by the Foundation. FASB ASU 2014-09 requires allocation of the transaction price to the performance obligation(s). Accordingly, the Foundation separately presents in its statement of activities and changes in net assets or notes to financial statements the exchange and contribution components of the gross proceeds from special events. Special event fees collected by the Foundation in advance of its delivery are initially recognized as liabilities (deferred revenue) and recognized as special event revenue after delivery of the event. For special event fees received before year-end for an event to occur after year-end, the Foundation follows AICPA guidance where the inherent contribution is conditioned on the event taking place and is therefore treated as a refundable advance along with the exchange component.

NORTHEAST LOUISIANA SICKLE CELL ANEMIA FOUNDATION, INC.
NOTES TO FINANCIAL STATEMENTS (CONTINUED)
JUNE 30, 2020

NOTE 1 - NATURE OF ACTIVITIES AND SUMMARY OF SIGNIFICANT ACCOUNTING
POLICIES: (Continued)

Public Support and Revenue

Grants and other contributions of cash and other assets are reported as support with donor restrictions if they are received with donor stipulations that limit the use of the donated assets. When a donor restriction expires, that is, when a stipulated time restriction ends or purpose restriction is accomplished, net assets with donor restrictions are reclassified to net assets without donor restrictions and reported in the statement of activities as net assets released from restrictions. Contributions received with donor-imposed restrictions that are met in the same year in which the contributions are received are classified as contributions without donor restrictions.

Contributions of donated noncash assets are recorded at their fair values in the period received. Contributions of donated services that created or enhance nonfinancial assets or that require specialized skills, are provided by individuals possessing those skills, and would typically need to be purchased if not provided by donation, are recorded at their fair values in the period received.

The accounting and reporting of grants is determined by the underlying substance of the transaction. A grant may be accounted for as contribution, an exchange transaction, or a combination of the two. If it is determined to be a contribution, a grant may be considered a conditional or an unconditional grant.

Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires the use of management's estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ from those estimates.

NORTHEAST LOUISIANA SICKLE CELL ANEMIA FOUNDATION, INC.
NOTES TO FINANCIAL STATEMENTS (CONTINUED)
JUNE 30, 2020

NOTE 1 - NATURE OF ACTIVITIES AND SUMMARY OF SIGNIFICANT ACCOUNTING
POLICIES: (Continued)

Income Taxes

The Foundation is exempt from federal income taxes under Section 501(c)(3) of the Internal Revenue Code. The Foundation believes that it has appropriate support for any tax provisions taken, and as such, does not have any uncertain tax positions that are material to the financial statements. The Foundations' Federal Return of Organization Exempt from Income Tax (form 990) for the years ended June 30, 2017, 2018, 2019, and 2020 are subject to examination by the IRS.

Advertising

The Foundation expenses advertising costs as they are incurred. For the year ended June 30, 2020, advertising expense was immaterial.

Reserve for Bad Debts

Accounts receivable are reviewed by management for bad debts monthly and it has been determined that there is no requirement for an allowance for doubtful accounts as of June 30, 2020.

Donated Services - Volunteers

No amounts have been reported in the financial statements for donated goods and services because no objective basis is available to measure the value of such services. Board members receive no compensation for services provided.

Cash and Cash Equivalents

For purposes of the statement of cash flows, the Foundation considers all unrestricted highly liquid investments with an original maturity of three months or less to be cash equivalents. Fair value approximates carrying amounts.

NORTHEAST LOUISIANA SICKLE CELL ANEMIA FOUNDATION, INC.
NOTES TO FINANCIAL STATEMENTS (CONTINUED)
JUNE 30, 2020

NOTE 1 - NATURE OF ACTIVITIES AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: (Continued)

Depreciation

The Foundation follows the practice of capitalizing, at cost, all expenditures for fixed assets in excess of \$5,000. Depreciation is computed on a straight-line basis over the useful lives of the assets generally as follows:

Building and Improvements	30 Years
Furniture and Equipment	7 Years
Computers and Accessories	5 Years

Fair Value of Financial Instruments

The carrying amounts of cash, cash equivalents, investments, and notes payable are reported in the statement of financial position at approximate fair values because of the short maturity of those instruments.

New Accounting Pronouncements

As of July 1, 2019, the Foundation adopted the provisions of Financial Accounting Standards Board (FASB) Accounting Standards Update (ASU) 2014-09, *Revenue from Contracts with Customers* (Topic 606), as amended. ASU 2014-09 applies to exchange transactions with customers that are bound by contracts or similar arrangements and establishes a performance obligation approach to revenue recognition. Results for reporting the year ending June 30, 2020 is presented under FASB ASC Topic 606. The ASU has been applied retrospectively, with no effect on net assets or previously issued financial statements.

During the year, the Foundation also adopted the provisions of FASB ASU 2018-08, *Clarifying the Scope and the Accounting Guidance for Contributions Received and Contributions Made* (Topic 958). This accounting standard is meant to help not-for-profit entities evaluate whether transactions should be accounted for as contributions or as exchange transactions and, if the transaction is identified as a contribution,

NORTHEAST LOUISIANA SICKLE CELL ANEMIA FOUNDATION, INC.
NOTES TO FINANCIAL STATEMENTS (CONTINUED)
JUNE 30, 2020

NOTE 1 - NATURE OF ACTIVITIES AND SUMMARY OF SIGNIFICANT ACCOUNTING
POLICIES: (Continued)

New Accounting Pronouncements (Continued)

whether it is conditional or unconditional. ASU 2018-08 clarifies how an organization determines whether a resource provider is receiving commensurate value in return for a grant. If the resource provider does receive commensurate value from the grant recipient, the transaction is an exchange transaction and would follow the guidance under ASU 2014-09 (FASB ASC Topic 606). If no commensurate value is received by the grant maker, the transfer is a contribution. ASU 2018-08 stresses that the value received by the general public as a result of the grant is not considered to be commensurate value received by the provider of the grant. Results for reporting the year ending June 30, 2020 are presented under FASB ASU 2018-08. There was no material impact to the financial statements as a result of adoption. Accordingly, no adjustment to opening net assets was recorded.

In 2020, the Foundation adopted the provisions of FASB ASU 2016-18, *Statement of Cash Flows* (Topic 230). This ASU requires that a statement of cash flows explain the change during the period in the total cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. Therefore, amounts generally described as restricted cash and restricted cash equivalents should be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the consolidated statement of cash flows. The amendments in the ASU do not provide a definition of restricted cash or restricted cash equivalents. The Foundation has applied the provisions of ASU 2016-18 with no effect on net assets or previously issued financial statements.

NOTE 2 - NET ASSETS WITH DONOR RESTRICTIONS:

The donor restrictions on net assets for the year ended June 30, 2020 were \$5,206 and relate to Walkathon funding.

NORTHEAST LOUISIANA SICKLE CELL ANEMIA FOUNDATION, INC.
 NOTES TO FINANCIAL STATEMENTS (CONTINUED)
 JUNE 30, 2020

NOTE 3 - PROPERTY AND EQUIPMENT:

Property and equipment consisted of the following at June 30, 2020:

	<u>7/01/2019</u>	<u>Additions</u>	<u>Deletions</u>	<u>6/30/2020</u>
Furniture and Equipment	27,585	-	-	27,585
Building	212,444	-	-	212,444
Vehicle	16,342	20,907	(16,342)	20,907
Less Accumulated				
Depreciation	(130,202)	(10,431)	16,342	(124,291)
Subtotal	126,169	10,476	-0-	136,645
Land	1,000	-0-	-0-	1,000
<u>Total</u>	<u>127,169</u>	<u>10,476</u>	<u>-0-</u>	<u>137,645</u>

Depreciation expense for the year ended June 30, 2020 was \$10,431.

NOTE 4 - COMPENSATED ABSENCES:

Compensated absences are absences for which employees will be paid, such as vacation, sick leave, and sabbatical leave. The Foundation has no policy for compensated absences. Therefore, those costs are not reflected in this report. However, for the purpose of this report the amounts are considered immaterial.

NOTE 5 - DEFERRED REVENUE:

Deferred revenue consists of the following:

United Way Funding	135,391
State of Louisiana Grant for Use in Next Fiscal Period	<u>14,050</u>
<u>Total</u>	<u>149,441</u>

NOTE 6 - FUNCTIONAL ALLOCATION OF EXPENSES:

The costs of providing the various programs and activities have been summarized on a functional basis in the statement of activities. Accordingly, certain costs have been allocated among the programs and supporting services benefitted.

NORTHEAST LOUISIANA SICKLE CELL ANEMIA FOUNDATION, INC.
NOTES TO FINANCIAL STATEMENTS (CONTINUED)
JUNE 30, 2020

NOTE 7 - FUND DESCRIPTION:

For internal accounting purposes, the Foundation maintains the following separate funds:

General Fund

All assets over which the Board of Directors has discretionary control have been included in the General Fund.

United Way Fund

The United Way Fund is used to account for a grant from United Way of Northeast Louisiana.

Genetic Disease Fund

The Genetic Disease Fund is used to account for a state grant from the Louisiana Department of Health and Hospitals.

Walkathon Fund

The Walkathon Fund is used to account for proceeds from an annual fundraiser.

NOTE 8 - LINE OF CREDIT:

The Foundation has a line of credit with Iberia Bank in the amount of \$4,118 with interest at 4.25%.

NOTE 9 - SUBSEQUENT EVENTS:

Events that occur after the balance sheet date but before the financial statements were issued must be evaluated for recognition or disclosure. The effects of subsequent events that provide evidence about conditions that existed after the balance sheet date require disclosure in the accompanying notes. Management evaluated the activity of the Foundation through October 26, 2020, the date the report was available for issue, and concluded that no subsequent events

NORTHEAST LOUISIANA SICKLE CELL ANEMIA FOUNDATION, INC.
NOTES TO FINANCIAL STATEMENTS (CONTINUED)
JUNE 30, 2020

NOTE 9 - SUBSEQUENT EVENTS: (Continued)

have occurred that would require recognition in the financial statements or disclosures in the notes to the financial statements.

NOTE 10 - LIQUIDITY AND AVAILABILITY OF FINANCIAL ASSETS:

The following reflects the Foundation's financial assets as of the balance sheet date of June 30, 2020, reduced by amounts not available for general use because of contractual or donor-imposed restrictions within one year of the balance sheet date.

Financial Assets at June 30, 2020	56,015
Less those unavailable for general expenditure within one year, due to:	
Donor Restrictions	<u>5,206</u>
Financial assets availability to meet cash needs for general expenditure, within one year	<u>50,809</u>

In addition to financial assets available to meet general expenditures over the year, the Foundation anticipates covering its general expenditures using the income generated from dues, contributions, and fund-raising events.

NOTE 11 - FUND-RAISING ACTIVITIES:

Details of the special fund-raising events summarized on the statement of activities are as follows:

Banquet Fund-Raising Revenue	4,500
Direct Benefit Costs (Exchange Transaction)	<u>(8,507)</u>
Net (Contribution)	<u>(4,007)</u>
<u>Total Net Fund-Raising Revenue</u>	<u>(4,007)</u>

Other fund-raising costs were not material.

NORTHEAST LOUISIANA SICKLE CELL ANEMIA FOUNDATION, INC.
NOTES TO FINANCIAL STATEMENTS (CONTINUED)
JUNE 30, 2020

NOTE 12 - CONCENTRATION OF CREDIT RISK:

All cash funds are in institutions insured by an agency of the federal government.

SUPPLEMENTAL INFORMATION

NORTHEAST LOUISIANA SICKLE CELL ANEMIA FOUNDATION, INC.
 SCHEDULE OF FINANCIAL POSITION
 FOR THE YEAR ENDED JUNE 30, 2020

	Without Donor Restrictions	<u>With Donor Restrictions</u>			Total All Funds
	General Fund	United Way Fund	Genetic Disease Fund	Walkathon Fund	
		<u>Assets</u>			
Current Assets					
Cash and Cash Equivalents	23,477	9,742	22,796	-	56,015
Receivables	-	-	-	-	-
Due from Other Funds	8,746	125,649	-	5,206	139,601
<u>Total Current Assets</u>	<u>32,223</u>	<u>135,391</u>	<u>22,796</u>	<u>5,206</u>	<u>195,616</u>
Investments	-	-	-	-	-
Physical Properties					
Furniture and Equipment	26,939	-	645	-	27,584
Building	212,444	-	-	-	212,444
Vehicle	20,907	-	-	-	20,907
Accumulated Depreciation	(123,645)	-	(645)	-	(124,290)
Land	1,000	-	-	-	1,000
<u>Total Physical Properties</u>	<u>137,645</u>	<u>-</u>	<u>-</u>	<u>-0-</u>	<u>137,645</u>
<u>Total Assets</u>	<u>169,868</u>	<u>135,391</u>	<u>22,796</u>	<u>5,206</u>	<u>333,261</u>
		<u>Liabilities and Net Assets</u>			
Current Liabilities					
Accrued Liabilities	-	-	-	-	-
Due to Other Funds	130,855	-	8,746	-	139,601
Deferred Revenue	-	135,391	14,050	-	149,441
Line of Credit	4,118	-	-	-	4,118
<u>Total Current Liabilities</u>	<u>134,973</u>	<u>135,391</u>	<u>22,796</u>	<u>-0-</u>	<u>293,160</u>
Long-Term Liabilities	-	-	-	-	-
<u>Total Long-Term Liabilities</u>	<u>-0-</u>	<u>-0-</u>	<u>-0-</u>	<u>-0-</u>	<u>-0-</u>
<u>Total Liabilities</u>	<u>134,973</u>	<u>135,391</u>	<u>22,796</u>	<u>-0-</u>	<u>293,160</u>

See Independent Auditors' Report and Accompanying Notes.

NORTHEAST LOUISIANA SICKLE CELL ANEMIA FOUNDATION, INC.
SCHEDULE OF FINANCIAL POSITION (CONTINUED)
FOR THE YEAR ENDED JUNE 30, 2020

	Without Donor Restrictions	With Donor Restrictions			Total All Funds
	General Fund	United Way Fund	Genetic Disease Fund	Walkathon Fund	
<u>Liabilities and Net Assets</u>					
Net Assets					
Without Donor Restrictions	34,895	-	-	-	34,895
With Donor Restrictions	-	-	-	5,206	5,206
<u>Total Net Assets</u>	<u>34,895</u>	<u>-0-</u>	<u>-0-</u>	<u>5,206</u>	<u>40,101</u>
 <u>Total Liabilities and Net Assets</u>	 <u>169,868</u>	 <u>135,391</u>	 <u>22,796</u>	 <u>5,206</u>	 <u>333,261</u>

See Independent Auditors' Report and Accompanying Notes.

NORTHEAST LOUISIANA SICKLE CELL ANEMIA FOUNDATION, INC.
SCHEDULE OF ACTIVITIES
FOR THE YEAR ENDED JUNE 30, 2020

	Without Donor Restrictions	With Donor Restrictions			Total All Funds
	General Fund	United Way Fund	Genetic Disease Fund	Walkathon Fund	
<u>Changes in Net Assets Without Donor Restrictions</u>					
Contributions	26,629	-	-	-	26,629
Other Income	10,337	-	-	-	10,337
Investment Income	517	-	-	-	517
Special Events	(4,007)	-	-	-	(4,007)
<u>Total Revenue and Gains Without Donor Restrictions</u>	<u>33,476</u>	<u>-0-</u>	<u>-0-</u>	<u>-0-</u>	<u>33,476</u>
<u>Net Assets Released from Restrictions</u>					
Restrictions Satisfied by Payments	<u>66,920</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>66,920</u>
<u>Total Net Assets Released from Restrictions</u>	<u>66,920</u>	<u>-0-</u>	<u>-0-</u>	<u>-0-</u>	<u>66,920</u>
<u>Total Revenue Gains And Other Support Without Donor Restrictions</u>					
	<u>100,396</u>	<u>-0-</u>	<u>-0-</u>	<u>-0-</u>	<u>100,396</u>
<u>Expenses</u>					
Program Expenses	58,790	-	-	-	58,790
General and Administrative Expenses	<u>56,550</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>56,550</u>
<u>Total Expenses</u>	<u>115,340</u>	<u>-0-</u>	<u>-0-</u>	<u>-0-</u>	<u>115,340</u>
<u>Increase (Decrease) in Net Assets Without Donor Restrictions</u>					
	<u>(14,944)</u>	<u>-0-</u>	<u>-0-</u>	<u>-0-</u>	<u>(14,944)</u>

See Independent Auditors' Report and Accompanying Notes.

NORTHEAST LOUISIANA SICKLE CELL ANEMIA FOUNDATION, INC.
SCHEDULE OF ACTIVITIES (CONTINUED)
FOR THE YEAR ENDED JUNE 30, 2020

	Without Donor Restrictions	<u>With Donor Restrictions</u>			Total <u>All Funds</u>
	General <u>Fund</u>	United Way <u>Fund</u>	Genetic Disease <u>Fund</u>	Walkathon <u>Fund</u>	
<u>Changes in Net Assets With Donor Restrictions</u>					
Contributions	-	-	-	-	-
Grants	-	25,720	41,200	-	66,920
Net Assets Released from Restrictions					
Restrictions Satisfied by Payments	-	(25,720)	(41,200)	-	(66,920)
 <u>Increase (Decrease) in Net Assets With Donor Restrictions</u>					
	-0-	-0-	-0-	-0-	-0-
Change in Net Assets	(14,944)	-	-	-	(14,944)
 <u>Net Assets at Beginning of Year</u>					
	49,839	-	-	5,206	55,045
 <u>Net Assets at End of Year</u>					
	34,895	-0-	-0-	5,206	40,401

See Independent Auditors' Report and Accompanying Notes.

NORTHEAST LOUISIANA SICKLE CELL ANEMIA FOUNDATION, INC.
 SCHEDULE OF CASH FLOWS
 FOR THE YEAR ENDED JUNE 30, 2020

	Without Donor Restrictions	<u>With Donor Restrictions</u>			Total All Funds
	General Fund	United Way Fund	Genetic Disease Fund	Walkathon Fund	
<u>Operating Activities</u>					
Change in Net Assets	(14,944)	-	-	-	(14,944)
Adjustments to Reconcile Change in Net Assets to Net Cash Provided by Operating Activities:					
Provision for Depreciation	10,431	-	-	-	10,431
Decrease (Increase) in Due from Other Funds	11,367	1,623	-	-	12,990
Increase (Decrease) in Grants Receivable	-	-	4,900	-	4,900
Accrued Liabilities Due to Other Funds	(1,623)	-	(11,367)	-	(12,990)
Deferred Revenue	-	2,984	14,050	-	17,034
Total Adjustments	<u>20,175</u>	<u>4,607</u>	<u>7,583</u>	<u>-</u>	<u>32,365</u>
<u>Net Cash Provided by Operating Activities</u>	<u>5,231</u>	<u>4,607</u>	<u>7,583</u>	<u>-0-</u>	<u>17,421</u>

See Independent Auditors' Report and Accompanying Notes.

NORTHEAST LOUISIANA SICKLE CELL ANEMIA FOUNDATION, INC.
SCHEDULE OF CASH FLOWS (CONTINUED)
FOR THE YEAR ENDED JUNE 30, 2020

	Without Donor Restrictions	With Donor Restrictions			Total All Funds
	General Fund	United Way Fund	Genetic Disease Fund	Walkathon Fund	
<u>Investing Activities</u>					
Purchase of Fixed Assets	(20,907)	-	-	-	(20,907)
Proceeds from CD	<u>21,986</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>21,986</u>
<u>Net Cash Provided by Investing Activities</u>	<u>1,079</u>	<u>-0-</u>	<u>-0-</u>	<u>-0-</u>	<u>1,079</u>
<u>Financing Activities</u>					
Proceeds from Line of Credit	<u>239</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>239</u>
<u>Net Cash Provided by Financing Activities</u>	<u>239</u>	<u>-0-</u>	<u>-0-</u>	<u>-0-</u>	<u>239</u>
<u>Net Increase (Decrease) in Cash</u>	6,549	4,607	7,583	-	18,739
<u>Cash and Cash Equivalents at Beginning of Year</u>					
	<u>16,928</u>	<u>5,135</u>	<u>15,213</u>	<u>-</u>	<u>37,276</u>
<u>Cash and Cash Equivalents at End of Year</u>					
	<u>23,477</u>	<u>9,742</u>	<u>22,796</u>	<u>-0-</u>	<u>56,015</u>

See Independent Auditors' Report and Accompanying Notes.

NORTHEAST LOUISIANA SICKLE CELL ANEMIA FOUNDATION, INC.
SCHEDULE OF FUNCTIONAL EXPENSES
JUNE 30, 2020

	Net Assets with Donor Restrictions Released From Restriction				Total All Funds
	General Fund	United Way Fund	Genetic Disease Fund	Walkathon Fund	
<u>Program Expenses</u>					
<u>Personnel Costs</u>					
Salaries and Wages	1,067	13,428	13,132	-	27,627
Payroll Taxes and Other Fringe Benefits	93	1,173	1,147	-	2,413
<u>Total Personnel Costs</u>	<u>1,160</u>	<u>14,601</u>	<u>14,279</u>	<u>-0-</u>	<u>30,040</u>
<u>Other Expenses</u>					
Advertising	65	-	-	-	65
Automobile Expense	135	-	-	-	135
Bank Charges	279	-	-	-	279
Depreciation Expense	5,633	-	-	-	5,633
Insurance	2,055	-	-	-	2,055
Interest	249	-	-	-	249
Maintenance	671	-	-	-	671
Office Expense	4,203	-	-	-	4,203
Postage and Delivery	72	-	-	-	72
Printing and Publication	588	-	-	-	588
Program Expenses	38	-	-	-	38
Repairs and Maintenance	438	-	-	-	438
Specific Assistance to Individuals	6,884	-	-	-	6,884
Storage	291	-	-	-	291
Telephone	927	-	-	-	927
Travel	-	-	-	-	-
Utilities	3,662	2,560	-	-	6,222
<u>Total Other Expenses</u>	<u>26,190</u>	<u>2,560</u>	<u>-0-</u>	<u>-0-</u>	<u>28,750</u>
<u>Total Program Expenses</u>	<u>27,350</u>	<u>17,161</u>	<u>14,279</u>	<u>-0-</u>	<u>58,790</u>

See Independent Auditors' Report and Accompanying Notes.

NORTHEAST LOUISIANA SICKLE CELL ANEMIA FOUNDATION, INC.
SCHEDULE OF FUNCTIONAL EXPENSES (CONTINUED)
JUNE 30, 2020

	Net Assets with Donor Restrictions Released From Restriction				Total
	General	United	Genetic	Walkathon	All Funds
	<u>Fund</u>	<u>Fund</u>	<u>Fund</u>	<u>Fund</u>	
<u>General and Administrative Expenses</u>					
<u>Personnel Costs</u>					
Salaries and Wages	1,067	-	24,759	-	25,826
Payroll Taxes and Other Fringe Benefits	<u>93</u>	<u>-</u>	<u>2,162</u>	<u>-</u>	<u>2,255</u>
<u>Total Personnel Costs</u>	<u>1,160</u>	<u>-</u>	<u>26,921</u>	<u>-</u>	<u>28,081</u>
<u>Other Expenses</u>					
Advertising	56	-	-	-	56
Automobile Expense	115	-	-	-	115
Bank Charges	238	-	-	-	238
Depreciation Expense	4,798	-	-	-	4,798
Interest Expense	213	-	-	-	213
Insurance	1,750	-	-	-	1,750
Maintenance	571	-	-	-	571
Office Expense	3,586	-	-	-	3,586
Other Program Expense	32	-	-	-	32
Postage and Delivery	62	-	-	-	62
Printing and Publication	500	-	-	-	500
Professional Fees	3,838	6,000	-	-	9,838
Repairs and Maintenance	373	-	-	-	373
Storage	247	-	-	-	247
Telephone	790	-	-	-	790
Travel	-	-	-	-	-
Utilities	<u>2,741</u>	<u>2,559</u>	<u>-</u>	<u>-</u>	<u>5,300</u>
<u>Total Other Expenses</u>	<u>19,910</u>	<u>8,559</u>	<u>-0-</u>	<u>-0-</u>	<u>28,469</u>

See Independent Auditors' Report and Accompanying Notes.

NORTHEAST LOUISIANA SICKLE CELL ANEMIA FOUNDATION, INC.
SCHEDULE OF FUNCTIONAL EXPENSES (CONTINUED)
JUNE 30, 2020

	Net Assets with Donor Restrictions Released From Restriction				
General Fund	United Way Fund	Genetic Disease Fund	Walkathon Fund	Total All Funds	
<u>Total General and Administrative Expenses</u>	<u>21,070</u>	<u>8,559</u>	<u>26,921</u>	-	<u>56,550</u>
<u>Total Functional Expenses</u>	<u>48,420</u>	<u>25,720</u>	<u>41,200</u>	<u>-0-</u>	<u>115,340</u>

See Independent Auditors' Report and Accompanying Notes.

NORTHEAST LOUISIANA SICKLE CELL ANEMIA FOUNDATION, INC.
 SCHEDULE OF COMPENSATION, BENEFITS, AND OTHER PAYMENTS TO
 AGENCY HEAD OR CHIEF EXECUTIVE OFFICER
 FOR THE YEAR ENDED JUNE 30, 2020

AGENCY HEAD NAME/TITLE: DONNA THAXTON, EXECUTIVE DIRECTOR

<u>Purpose</u>	<u>Amount Paid</u>
Salary	27,840
Benefits-insurance	-0-
Benefits-retirement	-0-
Benefits-other (describe)	-0-
Benefits-other (describe)	-0-
Benefits-other (describe)	-0-
Car allowance	-0-
Vehicle provided by government (enter amount reported on W-2)	-0-
Per diem	-0-
Reimbursements	157
Travel	-0-
Registration Fees	-0-
Conference travel	-0-
Housing	-0-
Unvouchered expenses (example: travel advances, etc.)	-0-
Special meals	-0-
Other - Training	-0-

See Independent Auditors' Report and Accompanying Notes.

COMPLIANCE REPORTS

JOHNSON, PERRY, ROUSSEL & CUTHBERT, L.L.P.

ROWLAND H. PERRY, CPA, APC
CHARLES L. JOHNSON, JR., CPA
VIOLET M. ROUSSEL, CPA, APC
JAY CUTHBERT, CPA, APAC

PAM BATTAGLIA, CPA
DAWN WHITSTINE, CPA
JOHN R. FORSELL, IV, CPA



America Counts on CPAs®

Certified Public Accountants

3007 Armand Street

Monroe, Louisiana 71201

Telephone (318) 322-5156 or (318) 323-1411

Facsimile (318) 323-6331

- Accounting & Auditing
 - HUD Audits
 - Non-Profit Organizations
 - Governmental Organizations
- Business & Financial Planning
- Tax Preparation & Planning
 - Individual & Partnership
 - Corporate & Fiduciary
- Bookkeeping & Payroll Services

INDEPENDENT AUDITORS' REPORT ON INTERNAL CONTROL OVER FINANCIAL REPORTING AND ON COMPLIANCE AND OTHER MATTERS BASED ON AN AUDIT OF FINANCIAL STATEMENTS PERFORMED IN ACCORDANCE WITH GOVERNMENT AUDITING STANDARDS

Board of Directors
Northeast Louisiana Sickle Cell Anemia Foundation, Inc.
Monroe, Louisiana

We were engaged to audit, in accordance with the auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards* issued by the Comptroller General of the United States, the financial statements of the Northeast Louisiana Sickle Cell Anemia Foundation, Inc. (a nonprofit organization) as of and for the year ended June 30, 2020, and the related notes to the financial statements, and have issued our report thereon dated October 26, 2020.

Internal Control Over Financial Reporting

In planning and performing our audit, we considered Northeast Louisiana Sickle Cell Anemia Foundation, Inc.'s internal control over financial reporting (internal control) to determine the audit procedures that are appropriate in the circumstances for the purpose of expressing our opinions on the financial statements, but not for the purpose of expressing an opinion on the effectiveness of the Northeast Louisiana Sickle Cell Anemia Foundation, Inc.'s internal control. Accordingly, we do not express an opinion on the effectiveness of the Northeast Louisiana Sickle Cell Anemia Foundation, Inc.'s internal control.

A *deficiency in internal control* exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent or detect and correct misstatements on a timely basis. A *material weakness* is a deficiency, or a combination of deficiencies, in internal control such that there is a reasonable possibility that a material misstatement of

the entity's financial statements will not be prevented, or detected and corrected on a timely basis. A *significant deficiency* is a deficiency, or a combination of deficiencies, in internal control that is less severe than a material weakness, yet important enough to merit attention by those charged with governance.

Our consideration of internal control was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control that might be material weaknesses or significant deficiencies and therefore, material weaknesses or significant deficiencies may exist that were not identified. Given these limitations, during our audit we did not identify any deficiencies in internal control that we consider to be material weaknesses. However, material weaknesses may exist that have not been identified.

Compliance and Other Matters

As part of obtaining reasonable assurance about whether the Northeast Louisiana Sickle Cell Anemia Foundation, Inc.'s financial statements are free from material misstatement, we performed tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements, noncompliance with which could have a direct and material effect on the determination of financial statement amounts. However, providing an opinion on compliance with those provisions was not an objective of our audit, and accordingly, we do not express such an opinion. The results of our tests disclosed no instances of non-compliance or other matters that are required to be reported under *Government Auditing Standards*.

Purpose of This Report

The purpose of this report is solely to describe the scope of our testing of internal control and compliance and the result of that testing, and not to provide an opinion on the effectiveness of the entity's internal control or on compliance. This report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the entity's internal control and compliance. Accordingly, this communication is not suitable for any other purpose.

Johnson, Perry, Roussel & Cuthbert, LLP

JOHNSON, PERRY, ROUSSEL & CUTHBERT, L.L.P.
CERTIFIED PUBLIC ACCOUNTANTS
October 26, 2020

NORTHEAST LOUISIANA SICKLE CELL ANEMIA FOUNDATION, INC.
SCHEDULE OF FINDINGS AND QUESTIONED COSTS
FOR THE YEAR ENDED JUNE 30, 2020

Internal Control

There were no findings or questioned costs for the year ended June 30, 2020.

Compliance

There were no findings or questioned costs for the year ended June 30, 2020.

NORTHEAST LOUISIANA SICKLE CELL ANEMIA FOUNDATION, INC.
CORRECTIVE ACTION TAKEN ON PRIOR YEAR FINDINGS
JUNE 30, 2020

2019-001

Finding: There was an inadequate segregation of duties.

Status: Cleared